Drug Discovery@nature.com 5 September 2014

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS 5 September 2014 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Nature Biotechnology  ANIMATION: ANTIBODY-DRUG CONJUGATES The challenges facing targeted delivery of antibody-drug conjugates to a tumor are presented in a 3D animation that describes some of the mechanisms by which these agents target cells. Animation by Nucleus Inc. Produced with support from Daiichi Sankyo and Takeda Pharmaceuticals      News Top Bank tests drug development waters doi:10.1038/nrd4412 The European Investment Bank has invested 75 million euros in a risk-sharing drug development deal with the pharmaceutical company UCB, potentially opening up a new source of research and development (R&D) funding. Full Text Trial watch: Atopic dermatitis therapy breakthrough on the horizon? doi:10.1038/nrd4414 Phase I and II studies published recently suggest that dupilumab, a monoclonal antibody that targets a subunit of the interleukin-4 (IL-4) and IL-13 receptors, has the potential to become the first systemic therapy for atopic dermatitis to be approved by the US Food and Drug Administration. Full Text Market watch: A framework for biomedical innovation in emerging markets doi:10.1038/nrd4413 This article describes a framework to help understand the relative strengths and weaknesses of biomedical innovation in emerging markets, including China, Russia, India and Brazil, and their potential evolution. Full Text Stelara safe after IL-12 antibody dispute doi:10.1038/nrd4423 AbbVie has lost a patent dispute in which it tried to show that Janssen's Stelara (ustekinumab) — an antibody binding to interleukin-12 (IL-12) and IL-23 that is marketed for the treatment of psoriasis and psoriatic arthritis — infringed on two patents describing IL-12-targeting antibodies owned by AbbVie. Full Text Analysis Top Overcoming ibrutinib resistance doi:10.1038/scibx.2014.971 The CDK4 inhibitor palbociclib might help overcome ibrutinib resistance in mantle cell lymphoma by restoring sensitivity to inhibitors of BTK or PI3K. Full Text The HIV pipeline doi:10.1038/nrd4364 This article provides an overview of the diverse anti-HIV agents in development, including combination therapies, and an analysis of the market for current and future HIV treatments. Full Text Research Highlights Top Anticancer drugs: Horizons broaden for PI3Kδ inhibitors doi:10.1038/nrd4399 Inhibitors of the p110δ isoform of PI3K could have therapeutic potential in a broad range of cancers. Full Text Analgesia: Anti-itch and anti-ouch antibody doi:10.1038/nrd4396 An antibody that targets sodium channel Nav1.7 could be useful for treating inflammatory or neuropathic pain, as well as itch-related disorders. Full Text Vaccines: HIV vaccine failure due to induction of immune suppressors? doi:10.1038/nrd4398 New findings show that vaccines can potentially induce suppressor cells and thereby dampen any specific immune responses. Full Text Research & Reviews Top Phenotypic screening in cancer drug discovery — past, present and future doi:10.1038/nrd4366 Moffat and colleagues investigate the contribution of phenotypic assays in anticancer drug development, and discuss technical and biological advances that could empower phenotypic drug discovery in oncology. Full Text Semaphorins and plexins as therapeutic targets doi:10.1038/nrd4337 Worzfeld and Offermanns summarize the pathological roles of semaphorins and plexins in cancer, bone diseases, immuno-inflammatory diseases and spinal cord injury, and discuss emerging strategies to therapeutically target these molecules. Full Text Therapeutic targeting of microRNAs: current status and future challenges doi:10.1038/nrd4359 Li and Rana discuss strategies in the design of micro RNA-targeting oligonucleotides with increased efficacy and improved in vivo delivery characteristics, and highlight some of the challenges ahead in the clinical development of these therapeutics. Full Text Drug Discovery JOBS of the week PhD scholarship in Drug Delivery Technical University of Denmark (DTU) Sweden Postdoctoral Opportunity in Drug Safety and Metabolism – Functional Molecular Imaging AstraZeneca Non-Clinical Drug Safety Manager SLS Services Ltd Head of Drug and RNAi Screening Platform UCLA Associate Scientist I, Drug Safety Evaluation Gilead Sciences More Science jobs from Drug Discovery EVENT Elucidating GPCR Functional Selectivity: Novel Opportunities for Drug Development 30.09.14 NY, US More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Advertisement An interdisciplinary journal dedicated to publishing high-quality open research relevant to all aspects of schizophrenia and psychosis, the journal is now open for submissions. Visit the website to explore the benefits of submitting your research.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.